By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panelists have a neutral to bearish sentiment on Amgen, with the key concern being the debt load from the Horizon acquisition and the risk of Uplizna's revenue not meeting expectations, which could strain the balance sheet and EPS growth.
Risk: The debt load from the Horizon acquisition and the risk of Uplizna's revenue not meeting expectations, which could strain the balance sheet and EPS growth.
Opportunity: Uplizna gaining meaningful traction in the gMG market and achieving high-margin scale to service the debt and drive EPS growth.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
With an annual dividend yield of 2.85%, Amgen Inc. (NASDAQ:AMGN) is included among the 12 High Yield Fortune 500 Stocks to Buy Now.
Amgen Inc. (NASDAQ:AMGN) discovers, develops, manufactures, and delivers innovative medicines to fight some of the world’s toughest diseases.
On June 10, Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen Inc. (NASDAQ:AMGN) from $322 to $340, while keeping an ‘Equal Weight’ rating on the shares. The boosted price goal still indicates a downside of over 4% from the current levels.
The US Food and Drug Administration (FDA) approved Amgen’s Uplizna as the first treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD) last year. The drug was later also approved by the European Commission as an add-on treatment to standard therapy for adults living with generalized myasthenia gravis (gMG) in February 2026.
Morgan Stanley noted that the launch of Uplizna for generalized myasthenia gravis (gMG) is “off to a strong start”. The firm believes that the gMG market has the potential to double to over $10 billion over the next five or so years, fueled by the introduction of new therapies and the rising adoption of biologics.
While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 High Yield Crude Oil Stocks to Buy Now and 10 Most Volatile Stocks to Buy in S&P 500
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"The price target increase reflects incremental progress in a single pipeline asset rather than a fundamental re-rating of Amgen's long-term growth trajectory."
Morgan Stanley’s price target hike to $340 while maintaining an 'Equal Weight' rating is a classic 'show me' signal. While Uplizna’s traction in the $10 billion gMG market is a clear tailwind, the market is already pricing in significant execution risk, hence the 4% downside to the new target. Amgen is currently navigating a transition from legacy blockbuster reliance to a more diversified portfolio, but the valuation is tight. With a 2.85% yield, it functions more as a defensive income play than a growth engine. Investors should focus on the R&D pipeline beyond Uplizna, as the stock’s premium depends on whether they can offset patent cliffs in the core portfolio.
The bull case ignores that the gMG market is becoming hyper-competitive with aggressive entrants like Argenx, which could compress margins despite the total market growth.
"A price target raise without a rating upgrade, combined with vague launch commentary and missing revenue specifics, suggests Morgan Stanley sees Uplizna as incremental upside, not transformative—insufficient to drive conviction."
Morgan Stanley raising AMGN's target from $322 to $340 while maintaining 'Equal Weight' is a red flag—that's a $18 bump with no conviction upgrade. The Uplizna gMG launch being 'off to a strong start' is vague; we need Q2 revenue data and patient uptake curves to validate the $10B market thesis. IgG4-RD approval last year hasn't been quantified in the article—what's actual penetration? The 2.85% dividend yield is solid but doesn't justify a 4% downside target from current levels if the drug story is truly compelling. The article also pivots to AI stocks mid-way, suggesting the author itself lacks conviction on biotech momentum.
Uplizna could face faster-than-expected adoption in gMG (rare disease with high unmet need), and a $10B market in 5 years is conservative if biologics adoption accelerates; Morgan Stanley may be sandbagging the target to avoid upside surprise.
"The PT raise to $340 with an Equal Weight rating signals limited conviction and potential near-term downside despite Uplizna momentum."
Morgan Stanley's hike of Amgen's PT to $340 from $322 keeps an Equal Weight rating, implying over 4% downside from current prices around $355. While Uplizna's gMG launch shows early traction and the broader market could reach $10B, the analyst's stance signals caution rather than conviction. The article's pivot to promoting AI stocks further dilutes focus on AMGN's fundamentals. Missing context includes exact Q1 or Q2 Uplizna sales figures and competition in the IgG4-RD and gMG spaces. This modest revision may reflect tempered expectations on adoption speed or pricing power.
Strong early gMG uptake could still drive outsized revenue if the market doubles, potentially forcing Morgan Stanley to revisit its Equal Weight stance and lift the target well above current levels within 12 months.
"Amgen could see meaningful near-to-mid-term uplift if Uplizna secures rapid, broad payer adoption and label expansion, but this hinges on execution and regulatory clarity more than current price upside."
Morgan Stanley's $340 target on AMGN implies only modest upside unless Uplizna gains meaningful traction in gMG. The bull thesis hinges on a potential range expansion of the gMG market toward $10B and broad payer coverage for Uplizna, which could lift Amgen beyond its legacy franchise growth. However, the article glosses over key risks: the regulatory status and timing of Uplizna's IgG4-RD indication (and EU-US rollout pace), potential competitive pressure from other biologics or CD19-targeted therapies, and payer-driven discounts that could cap margins on new launches. The upside rests on execution and label expansion over 3–5 years, not a guaranteed revenue windfall.
If uptake lags or regulatory/competitive dynamics derail Uplizna's expansion, Amgen's growth upside could be far smaller than implied, challenging the bullish case.
"The Horizon Therapeutics acquisition debt creates a significant drag on EPS that makes the current valuation unsustainable regardless of Uplizna's success."
Claude is right to flag the AI pivot as a distraction, but we are all missing the capital allocation risk. Amgen spent $27.8 billion on Horizon Therapeutics. That massive debt load is the real anchor, not just the pipeline execution. If Uplizna doesn't achieve immediate, high-margin scale, the interest expense on that acquisition will cannibalize the very EPS growth investors are banking on. We are over-focusing on drug labels while ignoring the balance sheet strain.
"Horizon's debt is a real constraint, but only if Uplizna underperforms—the threshold matters more than the absolute number."
Gemini's debt angle is sharp, but the $27.8B Horizon acquisition closed in 2023—that's already baked into current leverage metrics. The real test is whether Uplizna's gross margins (typically 80%+ for biologics) can service that debt faster than legacy portfolio decline. If Uplizna hits $2B+ revenue by 2026, interest burden becomes noise. The risk isn't the debt itself; it's if Uplizna stalls below $1.5B, forcing margin compression or asset sales. Nobody's quantified the breakeven revenue threshold.
"Competition from Argenx risks compressing Uplizna margins, prolonging Horizon debt impact beyond Claude's 2026 breakeven."
Claude overlooks how Argenx's competition in gMG could erode Uplizna's margins below the 80% biologic norm, even at $2B revenue. That would extend the debt service timeline from the $27.8B Horizon deal well beyond 2026, pressuring EPS more than acknowledged. The breakeven threshold rises if pricing power weakens under payer scrutiny and new entrants. This linkage between market competition and balance sheet strain remains unaddressed.
"AmGen's Horizon debt, under higher-for-longer rates, could cap EPS growth and limit upside from Uplizna."
Gemini's debt angle is the right anchor, but the key overlooked risk is rate sensitivity and refinancing risk. Amgen's ~$27.8B Horizon debt creates EPS leverage that could evaporate if interest costs rise or if refinancing costs bite; even strong Uplizna adoption won't deliver sustained upside if margins must service debt and fund pipeline. The article's scenario plan underweights the sensitivity of leverage to a higher-for-longer rate environment.
The panelists have a neutral to bearish sentiment on Amgen, with the key concern being the debt load from the Horizon acquisition and the risk of Uplizna's revenue not meeting expectations, which could strain the balance sheet and EPS growth.
Uplizna gaining meaningful traction in the gMG market and achieving high-margin scale to service the debt and drive EPS growth.
The debt load from the Horizon acquisition and the risk of Uplizna's revenue not meeting expectations, which could strain the balance sheet and EPS growth.